Abstracts tagged "SLE and thrombosis"

Abstract Number: 2428 • 2018 ACR/ARHP Annual Meeting
Correlation between Antibodies to the Phosphotidylserine/Prothrombin Complex (aPS/PT) and Anti-β2glycoprotein-1-Domain 1 (anti-β2GP1-D1) and Vascular Thrombosis (VT) and/or Pregnancy Morbidity (PM)
Eric Campbell¹, Tania Pannu¹, Marvin J. Fritzler², Michelle Jung³, Claire Barber⁴, Yvan St. Pierre⁵ and Ann E. Clarke², ¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ³Division of Rheumatology, University of Calgary, Calgary, AB, Canada, ⁴Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁵Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: aPS/PT is considered to be a risk factor for vascular thrombosis (VT) and/or pregnancy morbidity (PM). Anti-β2GP1-D1 is potentially superior to anti-β2GP1 in predicting…
Abstract Number: 2907 • 2015 ACR/ARHP Annual Meeting
The Natural History of Thrombotic Events in Systemic Lupus Erythematosus and Associated Risk Factors
Katharine Hickman¹, Laurence S Magder² and Michelle Petri³, ¹University College London, London, United Kingdom, ²University of Maryland School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University Hospital, Baltimore, MD
Background/Purpose: Prospective cohort studies of the natural history of thrombosis in SLE, including events before diagnosis are rare. No previous study has identified risk factors…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].